Ligand News and Research

RSS

New peptide triggers domino effect to suppress bladder cancer

Recently, a research team led by Professors Dahong Zhang and Qi Zhang from the Urology Department and the Institute of Urology at Zhejiang Provincial People's Hospital and the Translational Medicine Center discovered that a bladder tumor-targeting polyarginine peptide, R11, can directly bind to actin, destabilize the G-actin tetramer, and trigger the cascade breakdown of the actin-plectin-vimentin/ITGβ4 axis (referred to as the "cytoskeletal domino effect").

25 May 2026

Scientists reveal why common pancreatic precancer lesions rarely turn deadly

Spatial and single-cell analyses of human donor pancreata showed that PanIN epithelial cells gradually acquire cancer-like molecular features, while their surrounding stromal and immune environment remains closer to normal pancreatic tissue. The findings suggest that delayed or incomplete microenvironmental reprogramming may help explain why most PanIN lesions remain indolent rather than progressing to pancreatic cancer.

24 May 2026

Scientists map genetic variants behind prostate cancer therapy failure

Recently, the research group led by Dr. Dechao Feng, Lecturer at University College London (UCL) and Distinguished Research Fellow at Zhejiang Provincial People's Hospital, published a review entitled "Intratumoral Androgens and Genetic Variants Driving Therapy Resistance in Prostate Cancer".

22 May 2026

Harvard researchers outline roadmap to solve orphan receptor challenge

A new review highlights how synthetic biology, AI, and spatial omics could transform ligand-receptor discovery from one-by-one searches into network-level mapping.

22 May 2026

Engineered nanomaterials optimize delivery barriers in cancer immunotherapy

Cancer immunotherapy works by mobilizing the body's own immune system to recognize and destroy malignant cells.

20 May 2026

Glycocalyx modification boosts immune cell targeting against B lymphoma

A new study published in Engineering provides mechanistic insights into live-cell glycocalyx engineering and supports the rational design of next-generation adoptive cell therapies (ACTs) against B lymphoma, addressing limitations such as high costs and restricted antigen specificity in current treatments.

25 Apr 2026

Molecular keyhole discovery offers new hope for personalized pain therapies

Researchers at VIB, VUB, and KU Leuven have identified a tiny binding site, a molecular 'keyhole', in the TRPM3 ion channel, a crucial sensor in pain signaling.

21 Apr 2026

Researchers discover how cell membrane composition drives cancer proliferation

Cells are enveloped by a lipid membrane that gives them structure and provides a barrier between the cell and its environment.

17 Apr 2026

Study finds long COVID leaves a distinct immune signature in the blood

Researchers identified a small panel of inflammatory and neurology-related blood proteins that may help distinguish long COVID from recovery or no prior infection, while also showing that booster vaccination did not appear to worsen these protein responses in this cohort. The study also found that immune responses after reinfection differed from those seen after the first SARS-CoV-2 infection, suggesting altered long-term immune behavior in some previously infected individuals.

14 Apr 2026

FairJourney Bio opens Cryo-EM structural biology facility in San Diego

FairJourney Bio (FJBio), a global antibody discovery contract research organization (CRO), today announced the opening of its advanced cryo-electron microscopy (cryo-EM) structural biology facility in San Diego, California.

From FairJourney Biologics S.A. 13 Apr 2026

High affinity for immune receptors predicts antibody drug associated anaphylaxis risk

Antibody therapeutics are laboratory-made proteins designed to work like the body's natural antibodies. They are widely used to treat diseases such as cancer by binding to specific targets, including cancer cells or inflammatory molecules.

8 Apr 2026

APOE4 alters brain immunity and cognition differently in females and males

APOE4 drove sex-specific changes in meningeal immunity, lymphatic drainage, brain lipids, neuroinflammation, and cognition in mouse models, with females showing greater inflammatory and cognitive vulnerability. Suppressing innate immunity improved some cognitive outcomes in female E4/E4 mice but worsened them in male E4/E4 mice, underscoring the need for sex-tailored approaches.

29 Mar 2026

Optibrium introduces graphical interface for QuanSA to enhance ligand-based affinity predictions

Optibrium, a leading developer of software and AI solutions for molecular design, today announced a new QuanSA™ plugin for PyMOL, providing an intuitive Graphical User Interface (GUI) for its ligand-based binding affinity prediction method, part of the Company's BioPharmics 3D molecular modelling platform.

From Optibrium Ltd. 25 Mar 2026

New pathway explains poor response to bladder cancer immunotherapy

Researchers at the Icahn School of Medicine at Mount Sinai and the Mount Sinai Tisch Cancer Center have discovered a biological pathway that helps explain why some bladder cancers do not respond well to immunotherapy.

18 Mar 2026

Protein targeted by cancer drugs may help the body fight influenza

A protein already targeted by FDA-approved cancer drugs may also help the body fight influenza, according to new research from The Jackson Laboratory (JAX).

18 Mar 2026

New CAR-T cell therapy shows promise for treating osteosarcoma

Finding an effective treatment for osteosarcoma, the most common type of bone cancer in children and young adults, has puzzled medical researchers for 40 years.

17 Mar 2026

Gold nanoclusters may help detect diseases from blood samples

An extensive computational study by researchers from the University of Jyväskylä (Finland) predicted that gold nanoclusters could selectively recognize chiral biomolecules.

16 Mar 2026

Combined CDK4/6 and EGFR inhibition improves pancreatic cancer therapy

Clinically available KRAS inhibitors mainly target G12C, which is rare in PDAC and often acquires resistance. Oncogenic KRAS inactivates RB1 via CDK4/6, while RB1 mutation is rare.

13 Mar 2026

Defining the limits of immunotherapy in early small-cell lung cancer

Immunotherapy given during and after chemoradiation did not improve survival for study participants with limited-stage, small-cell lung cancer (SCLC) according to the results of an international clinical trial, NRG-LU005, led by NRG Oncology in collaboration with the Alliance for Clinical Trials in Oncology. The results are published in the Journal of Clinical Oncology.

13 Mar 2026

Machine learning model predicts chemical reactions to accelerate drug discovery

Drug discovery is like molecular Tetris. Chemists snap atoms together, adjusting the pieces until everything fits and suddenly, a molecule makes a promising new medicine.

9 Mar 2026